Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine.

[1]  M. Danta,et al.  Telbivudine for the treatment of chronic hepatitis B. , 2007, Drugs of today.

[2]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[4]  V. Soriano,et al.  Telbivudine: a new option for the treatment of chronic hepatitis B , 2007, Expert opinion on biological therapy.

[5]  M. Danta,et al.  Telbivudine for the treatment of chronic hepatitis B. , 2007, Drugs of Today.

[6]  S. Hadziyannis,et al.  Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B , 2007, Hepatology.

[7]  Huiling Yang,et al.  In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents , 2006, Antiviral therapy.

[8]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[9]  Y. Liu,et al.  Evolution of multi‐drug resistant hepatitis B virus during sequential therapy , 2006, Hepatology.

[10]  S. Hadziyannis.  New developments in the treatment of chronic hepatitis B , 2006, Expert opinion on biological therapy.

[11]  Hirotoshi Nakamura,et al.  Changes in viral loads of lamivudine‐resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy , 2006, Journal of medical virology.

[12]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  A. Lok,et al.  Antiviral options for the treatment of chronic hepatitis B. , 2006, The Journal of antimicrobial chemotherapy.

[14]  H. Lee,et al.  Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy , 2006, Hepatology.

[15]  M. Rizzetto,et al.  Performance of sequence analysis, INNO‐LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations , 2006, Journal of viral hepatitis.

[16]  Y. Liaw,et al.  Switching to adefovir monotherapy after emergence of lamivudine‐resistant mutations in patients with liver cirrhosis , 2006, Journal of viral hepatitis.

[17]  D. Mutimer.  Review article: hepatitis B and liver transplantation , 2006, Alimentary pharmacology & therapeutics.

[18]  S. Yu,et al.  Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil , 2006, Gut.

[19]  R. Perrillo.  Therapy of hepatitis B — Viral suppression or eradication? , 2006, Hepatology.

[20]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[21]  B. McMahon.  Selecting Appropriate Management Strategies for Chronic Hepatitis B: Who to Treat , 2006, The American Journal of Gastroenterology.

[22]  Y. Paik,et al.  The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B , 2005, Antiviral therapy.

[23]  A. Craxì,et al.  Treatment options in HBV. , 2006, Journal of hepatology.

[24]  Y. Liaw.  The current management of HBV drug resistance. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[26]  U. Akarca,et al.  Comparison of Sequence Analysis and INNO-LiPA HBV DR Line Probe Assay in Patients with Chronic Hepatitis B , 2005, Journal of chemotherapy.

[27]  H. Lee,et al.  Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus , 2005, Journal of Korean medical science.

[28]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[29]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[30]  V. Mazzaferro,et al.  Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine‐resistant mutants , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[31]  G. Alaimo,et al.  HBV-DNA Suppression and Disease Course in HBV Cirrhosis Patients on Long-Term Lamivudine Therapy , 2005, Antiviral therapy.

[32]  P. Katsinelos,et al.  Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine‐resistant hepatitis B e antigen‐negative chronic hepatitis B , 2005, Alimentary pharmacology & therapeutics.

[33]  Robert P Perrillo,et al.  Current treatment of chronic hepatitis B: benefits and limitations. , 2005, Seminars in liver disease.

[34]  Ching-lung Lai,et al.  Four years of lamivudine treatment in Chinese patients with chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[35]  M. Rizzetto,et al.  Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen‐negative chronic hepatitis B , 2004, Alimentary pharmacology & therapeutics.

[36]  P. Marcellin,et al.  Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy , 2004, Journal of viral hepatitis.

[37]  C. Katlama,et al.  In Vitro Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir , 2003, Antiviral therapy.

[38]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[39]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[40]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[41]  D. Pillay,et al.  Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. , 2000, The Journal of infectious diseases.

[42]  M. Buti,et al.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999, Hepatology.